| Check out webinars and podcasts featuring key opinion leaders. |
|
|
|
|
|
![NovoSeven® RT (Coagulation Factor VIIa [Recombinant])](images/novoseven-logo.png) |
| NovoSeven® RT is indicated for congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelets, and acquired hemophilia. |
|
|
|
|
 |
| Now streaming on our resources page. |
| Our professional resources page on the NovoSeven® RT website now features podcasts and webinars. Stream or watch content on how to recognize and treat bleeding disorders in women. |
|
|
|
| Selected Important Safety Information |
| WARNING: THROMBOSIS |
| |
• |
Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported |
|
| |
• |
Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT |
|
| |
• |
Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis |
|
|
| Warnings and Precautions |
| |
• |
Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance |
|
| |
• |
Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events |
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
|
 |
| Resources for your office. |
| Looking for educational materials about how NovoSeven® RT treats bleeds? Download, order, and share these professional resources with your team. |
|
|
|
|
|
|
| Resources for your patients. |
| Looking for indication-specific materials for patients you are treating with NovoSeven® RT? Download, share, and order these resources for your office. |
|
|
|
|
|
 |
| We’re here to help. |
| If you have patients looking for product support or additional programs, let us know. Your Novo Nordisk Hemophilia Therapy Manager (HTM) can point you to patient resources like free trial prescriptions, co-pay assistance, and more. |
|
|
|
|
|
| Indications and Usage |
| NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for: |
| |
• |
Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets |
|
| |
• |
Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia |
|
| Important Safety Information (cont’d) |
| Warnings and Precautions |
| |
• |
Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur |
|
| |
• |
Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed |
|
| |
• |
Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis |
|
| Adverse Reactions |
| |
• |
The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia |
|
| Drug Interactions |
| |
• |
Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII |
|
| Please click here for Prescribing Information. |
|
|
|
<%@ include view='hcpColoradoFooter' %>
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
NovoSeven® RT is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2020 Novo Nordisk All Rights Reserved. US20NSVN00124 August 2020 |
 |
|
|
|